Pro Share Advisors LLC Kymera Therapeutics, Inc. Transaction History

Pro Share Advisors LLC

$39.7 Billion
Q3 2024

A detailed history of Pro Share Advisors LLC transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Pro Share Advisors LLC holds 12,222 shares of KYMR stock, worth $512,835. This represents 0.0% of its overall portfolio holdings.

Number of Shares

12,222

Previous 9,250 32.13%

Holding current value

$512,835

Previous $276,000 109.42%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$30.16 - $52.4 $89,635 - $155,732	2,972 Added 32.13%	12,222 $578,000
Q2 2024 Aug 13, 2024	SELL	$29.85 - $39.42 $70,416 - $92,991	-2,359 Reduced 20.32%	9,250 $276,000
Q1 2024 May 08, 2024	BUY	$22.9 - $43.57 $40,647 - $77,336	1,775 Added 18.05%	11,609 $466,000
Q4 2023 Feb 14, 2024	BUY	$10.97 - $26.84 $107,878 - $263,944	9,834 New	9,834 $250,000
Q1 2023 May 11, 2023	SELL	$24.84 - $38.75 $27,845 - $43,438	-1,121 Reduced 11.93%	8,276 $245,000
Q4 2022 Feb 02, 2023	BUY	$19.57 - $30.92 $183,899 - $290,555	9,397 New	9,397 $234,000
Q2 2022 Aug 01, 2022	SELL	$14.13 - $42.55 $166,592 - $501,664	-11,790 Closed	0 $0
Q1 2022 May 10, 2022	SELL	$35.3 - $64.68 $104,240 - $191,000	-2,953 Reduced 20.03%	11,790 $499,000
Q4 2021 Feb 08, 2022	BUY	$49.91 - $65.56 $515,969 - $677,759	10,338 Added 234.69%	14,743 $935,000
Q3 2021 Nov 12, 2021	SELL	$47.8 - $66.66 $147,893 - $206,246	-3,094 Reduced 41.26%	4,405 $259,000
Q2 2021 Aug 13, 2021	BUY	$31.08 - $51.95 $233,068 - $389,573	7,499 New	7,499 $364,000

Others Institutions Holding KYMR

# of Institutions

184

Shares Held

64.4M

Call Options Held

50.6K

Put Options Held

81.7K

View Full List

About Kymera Therapeutics, Inc.

Ticker KYMR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,705,800
Market Cap $2.3B
Description
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...

More about KYMR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.

Account

Pro Share Advisors LLC Kymera Therapeutics, Inc. Transaction History